Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS

(REGN)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/20/2019 05/21/2019 05/22/2019 05/23/2019 05/24/2019 Date
302.57(c) 309.95(c) 320.09(c) 315.26(c) 311.64 Last
740 727 999 925 1 253 012 934 655 226 107 Volume
-0.78% +2.44% +3.27% -1.51% -1.15% Change
More quotes
Financials (USD)
Sales 2019 7 283 M
EBIT 2019 2 704 M
Net income 2019 1 896 M
Finance 2019 4 492 M
Yield 2019 -
Sales 2020 7 871 M
EBIT 2020 3 131 M
Net income 2020 2 343 M
Finance 2020 6 774 M
Yield 2020 -
P/E ratio 2019 18,53
P/E ratio 2020 15,79
EV / Sales2019 4,05x
EV / Sales2020 3,45x
Capitalization 33 962 M
More Financials
Company
Regeneron Pharmaceuticals specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Sales break down by activity as follows: - sales of products (61.2%); - supply of collaborative services (32.6%): working with Sanofi... 
Sector
Biotechnology & Medical Research
Calendar
06/14 | 10:30amShareholder meeting
More about the company
Surperformance© ratings of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on REGENERON PHARMACEUTICALS
05/23REGENERON PHARMACEUTICALS : Announces Upcoming Investor Conference Presentation
PR
05/17REGENERON PHARMACEUTICALS : Updated Libtayo Results Reinforce Durable and Substa..
AQ
05/17SANOFI : - Updated Libtayo Results Reinforce Durable and Substantial Response Ra..
AQ
05/14REGENERON PHARMACEUTICALS : FDA Approves EYLEA Injection for Diabetic Retinopath..
AQ
05/13REGENERON PHARMACEUTICALS : Says FDA Approves Eylea Injection for All Diabetic R..
DJ
05/08REGENERON PHARMACEUTICALS : Dupixent Approved for Severe Asthma by European Comm..
AQ
05/08SANOFI : - Dupixent Approved for Severe Asthma by European Commission
AQ
05/07REGENERON PHARMACEUTICALS : Regulation FD Disclosure (form 8-K/A)
AQ
05/07GLOBAL MARKETS LIVE : Alstom, Iliad, EuropaCorp, ArcelorMittal, Airbus, Anadarko..
05/07EU Approves Sanofi and Regeneron's Dupixent for Severe Asthma
DJ
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Sector news : Bio Therapeutic Drugs
05/21Global chemical firms urged to source responsibly after lethal China blast - ..
RE
05/15GILEAD SCIENCES : Novartis gets approval to sell Kymriah in Japan for $306,000
RE
05/10PATRICK THOMAS : Biotech Industry Woos Talent With Top Pay -- WSJ
DJ
05/09PATRICK THOMAS : Biotech Is Place to Be for Top Salaries
DJ
05/08GLOBAL MARKETS LIVE : Siemens, Airbus, Nestlé, Tesla…
More sector news : Bio Therapeutic Drugs
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 392 $
Spread / Average Target 24%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
Michael S. Brown Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS-14.30%33 962
GILEAD SCIENCES7.39%84 558
VERTEX PHARMACEUTICALS4.41%44 148
GENMAB12.69%11 076
SAREPTA THERAPEUTICS INC8.36%9 019
BEIGENE LTD--.--%7 637